PAREXEL International Receives New Coverage from Analysts at KeyCorp (PRXL)
Several other analysts have also recently commented on the stock. Analysts at Wells Fargo & Co. upgraded shares of PAREXEL International to a “priority list” rating in a research note on Thursday, June 26th. Separately, analysts at Zacks upgraded shares of PAREXEL International from a “neutral” rating to an “outperform” rating in a research note on Thursday, June 26th. They now have a $58.20 price target on the stock. Finally, analysts at William Blair upgraded shares of PAREXEL International from a “market perform” rating to an “outperform” rating in a research note on Thursday, June 26th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $55.40.
Shares of PAREXEL International (NASDAQ:PRXL) traded up 0.83% on Wednesday, hitting $53.61. The stock had a trading volume of 575,510 shares. PAREXEL International has a 52 week low of $37.53 and a 52 week high of $57.25. The stock has a 50-day moving average of $51.62 and a 200-day moving average of $50.16. The company has a market cap of $3.049 billion and a P/E ratio of 25.76.
PAREXEL International (NASDAQ:PRXL) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.02. The company had revenue of $492.40 million for the quarter, compared to the consensus estimate of $493.35 million. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. Analysts expect that PAREXEL International will post $2.14 EPS for the current fiscal year.
PAREXEL International Corporation (NASDAQ:PRXL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.